ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNSS Sunesis Pharmaceuticals Inc

5.32
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sunesis Pharmaceuticals Inc NASDAQ:SNSS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.32 4.72 4.75 0 01:00:00

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against Sunesis Pharmaceuticals, Inc. on Behal...

24/07/2015 11:17pm

Business Wire


Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart


From Oct 2019 to Oct 2024

Click Here for more Sunesis Pharmaceuticals Charts.

Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Sunesis Pharmaceuticals, Inc. (“Sunesis” or the “Company”) (NASDAQ: SNSS). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

If you purchased or otherwise acquired Sunesis shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The investigation concerns whether the Company and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the Company’s July 23, 2015, announcement that the United States Food and Drug Administration (“FDA”) will not approve its blood cancer drug Qinprezo. When this news reached the investing public, shares of Sunesis fell more than 70% causing investors harm.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Goldberg Law PC, Los AngelesMichael Goldberg, Esq. 800-977-7401Brian Schall, Esq. 800-977-7401info@goldberglawpc.comhttp://www.Goldberglawpc.comhttps://twitter.com/search?q=golberglawpc&src=typdhttps://www.facebook.com/pages/Goldberg-Law-PC/850505465033804?fref=ts

1 Year Sunesis Pharmaceuticals Chart

1 Year Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock